tag:blogger.com,1999:blog-781671514856579833.post8568293007746398199..comments2024-03-27T08:59:24.243-04:00Comments on Lympho Bob: ASCO: Choosing Treatments for Follicular LymphomaLymphomaniachttp://www.blogger.com/profile/17519575154615844854noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-781671514856579833.post-53108452732705709772015-06-08T07:36:58.617-04:002015-06-08T07:36:58.617-04:00Yes, you are correct. I was going by what the arti...Yes, you are correct. I was going by what the article said, a report of what Dr. Salles had to say: "A head-to-head study of rituximab vs obinutuzumab (GA101) showed no difference." I think it's definitely another arrow in the quiver, and I think it will be used more and more either in combination, or by itself when we have a better sense of which patients it might work on, based on genetic profiles. But I also think it's true that no one has been able to improve on Rituxan in a way that would make any of us forget about Rituxan any time soon....<br />BobLymphomaniachttps://www.blogger.com/profile/17519575154615844854noreply@blogger.comtag:blogger.com,1999:blog-781671514856579833.post-91532653617594416212015-06-06T09:21:14.385-04:002015-06-06T09:21:14.385-04:00Hi Bob,
You mention that "Obinutuzumab perfo...Hi Bob,<br /><br />You mention that "Obinutuzumab performs about as well (but not better)."<br /><br />This article (http://www.medscape.com/viewarticle/845906) says that Obinutuzmab works in patients who are refractory to rituximab. It seems like another good 'arrow' later down the road.Anonymousnoreply@blogger.com